Silver Nanoparticle Based Codelivery of Oseltamivir to Inhibit the Activity of the H1N1 Influenza Virus through ROS-Mediated Signaling Pathways

• DOI: 10.1021/acsami.6b06613
• Publication Date: 2016-09-02T12:54:45Z
• Authors: Yinghua Li; Zhengfang Lin; Mingqi Zhao; Tiantian Xu; Changbing Wang; Liang Hua; Hanzhong Wang; Huimin Xia; Bing Zhu
• Keywords: Oseltamivir; Silver nanoparticle

As the therapeutic agent for antiviral applications, clinical use of oseltamivir is limited with appearance drug-resistant viruses. It important to explore novel anti-influenza drugs. The activity silver nanoparticles (AgNPs) has attracted increasing attention in recent years and was a possibility be employed as biomedical intervention. Herein, we describe synthesis surface decoration AgNPs by using (OTV) properties inhibition drug resistance. Compared oseltamivir, oseltamivir-modified (Ag@OTV) have remarkable against H1N1 infection, less toxicity found MDCK cells controlled-potential electrolysis (CPE), MTT, transmission electron microscopy (TEM). Furthermore, Ag@OTV inhibited neuraminidase (NA) hemagglutinin (HA) then prevented attachment influenza virus host cells. investigations mechanism revealed that could block from infecting prevent DNA fragmentation, chromatin condensation, caspase-3. remarkably accumulation reactive oxygen species (ROS) activation AKT p53 phosphorylation. Silver nanoparticle based codelivery inhibits through ROS-mediated signaling pathways. These findings demonstrate promising efficient virucide H1N1.